

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

Therapeutic Registrations Only (Txca=Y)

67% of Calendar Year is Past

Committee	Base Accrual 2009	2010 Accrual to date	Percentage of Base Accrual	Projected 2010 Accrual	Projected Increase <Decrease> from Base	Accrual Last 12 Months	12 Month Increase <Decrease> from Base
BREAST	4059	1412	35%	2095	<1964>	2343	<1716>
GI	461	308	67%	457	<4>	439	<22>
GU	810	391	48%	580	<230>	642	<168>
GYN	0	23		34	34	23	23
LEUK	323	124	38%	184	<139>	193	<130>
LUNG	285	345	121%	512	227	468	183
LYMPH	102	118	116%	175	73	158	56
MELAN	111	34	31%	50	<61>	95	<16>
MMYEL	123	87	71%	129	6	125	2
TM	41	43	105%	64	23	52	11
	6315	2885		4281	<2034>	4538	<1777>

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

Non-Therapeutic Registrations Only

67% of Calendar Year is Past

Committee	Base Accrual 2009	2010 Accrual to date	Percentage of Base Accrual	Projected 2010 Accrual	Projected	Accrual	12 Month
					<Decrease> from Base	Last 12 Months	<Decrease> from Base
BREAST	64	27	42%	40	<24>	47	<17>
CC	33	212	642%	315	282	245	212
LEUK	328	68	21%	101	<227>	143	<185>
LUNG	55	24	44%	36	<19>	36	<19>
LYMPH	42	39	93%	58	16	58	16
MMYEL	75	65	87%	96	21	92	17
	597	435		645	48	621	24

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

All Initial Registrations

67% of Calendar Year is Past

Committee	Base Accrual 2009	2010 Accrual to date	Percentage of Base Accrual	Projected 2010 Accrual	Projected	Accrual Last 12 Months	12 Month
					<Decrease> from Base		<Decrease> from Base
BREAST	4123	1439	35%	2135	<1988>	2390	<1733>
CC	33	212	642%	315	282	245	212
GI	461	308	67%	457	<4>	439	<22>
GU	810	391	48%	580	<230>	642	<168>
GYN	0	23		34	34	23	23
LEUK	651	192	29%	285	<366>	336	<315>
LUNG	340	369	109%	548	208	504	164
LYMPH	144	157	109%	233	89	216	72
MELAN	111	34	31%	50	<61>	95	<16>
MMYEL	198	152	77%	226	28	217	19
TM	41	43	105%	64	23	52	11
	6912	3320		4926	<1986>	5159	<1753>

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

Therapeutic Registrations by SWOG Institutions Only (Txca=Y)

67% of Calendar Year is Past

Committee	Base Accrual 2009	2010 Accrual to date	Percentage of Base Accrual	Projected 2010 Accrual	Projected Increase <Decrease> from Base	Accrual Last 12 Months	12 Month Increase <Decrease> from Base
BREAST	2292	889	39%	1319	<973>	1459	<833>
GI	411	278	68%	412	1	395	<16>
GU	599	316	53%	469	<130>	506	<93>
GYN	0	23		34	34	23	23
LEUK	192	96	50%	142	<50>	141	<51>
LUNG	270	291	108%	432	162	399	129
LYMPH	95	91	96%	135	40	131	36
MELAN	97	34	35%	50	<47>	92	<5>
MMYEL	64	54	84%	80	16	73	9
TM	41	43	105%	64	23	52	11
	4061	2115		3138	<923>	3271	<790>

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

Non-Therapeutic Registrations by SWOG Institutions Only

67% of Calendar Year is Past

Committee	Base Accrual 2009	2010 Accrual to date	Percentage of Base Accrual	Projected 2010 Accrual	Projected Increase <Decrease> from Base	Accrual Last 12 Months	12 Month Increase <Decrease> from Base
BREAST	10	8	80%	12	2	9	<1>
CC	33	212	642%	315	282	245	212
LEUK	318	68	21%	101	<217>	143	<175>
LUNG	39	17	44%	25	<14>	21	<18>
LYMPH	42	39	93%	58	16	58	16
MMYEL	75	65	87%	96	21	92	17
	517	409		607	90	568	51

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

All Initial Registrations by SWOG Institutions

67% of Calendar Year is Past

Committee	Base Accrual 2009	2010 Accrual to date	Percentage of Base Accrual	Projected 2010 Accrual	Projected	Accrual	12 Month
					<Decrease> from Base	Last 12 Months	Increase <Decrease> from Base
BREAST	2302	897	39%	1331	<971>	1468	<834>
CC	33	212	642%	315	282	245	212
GI	411	278	68%	412	1	395	<16>
GU	599	316	53%	469	<130>	506	<93>
GYN	0	23		34	34	23	23
LEUK	510	164	32%	243	<267>	284	<226>
LUNG	309	308	100%	457	148	420	111
LYMPH	137	130	95%	193	56	189	52
MELAN	97	34	35%	50	<47>	92	<5>
MMYEL	139	119	86%	177	38	165	26
TM	41	43	105%	64	23	52	11
	4578	2524		3745	<833>	3839	<739>

Southwest Oncology Group Current and Projected Accrual by Committee

Data as of 03 Sep 2010

Initial Registrations to Cancer Control Studies

67% of Calendar Year is Past

Committee	Base Accrual 2009	2009 Accrual to date	Percentage of Base Accrual	Projected 2009 Accrual	Projected Increase <Decrease> from Base	Accrual Last 12 Months	12 Month Increase <Decrease> from Base
BREAST	188	41	22%	61	<127>	70	<118>
CC	33	212	642%	315	282	245	212
GU	496	160	32%	237	<259>	310	<186>
LUNG	81	24	30%	36	<45>	42	<39>
LYMPH	4	6	150%	9	5	9	5
	802	443		657	<145>	676	<126>

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Date of		
								Accrual Rate	Expected Closure or Temporary Closure	
BREAST	II	S0622 Breast, Adv, 2 sched Dasatinib	SWOG	15-MAR-07	41	76	80	1.8	Nov-2010	
		Z1071 Node+, chemo + LN dissect	ACOSOG	22-JUL-09		15		2.2		
		S0800 Brst,Neoadj nabPAC+/-Bev->AC+G	SWOG	01-APR-10	5	12	200	2.4	Apr-2017	
		C40603 Carb/Bev+Neoadj Pac, then AC/EC	CALGB	21-MAY-10		0		.0		
	III	C40101 Breast, Adj, Node neg, AC vs T	CALGB	15-MAY-02			733		1.5	
		JMA20 Breast, Early, Regional RT	NCIC	03-OCT-02			8		.0	
		IBC24-02 Ovar Ftn suppress/premeno	IBCSG	04-AUG-03			187		.3	
		S0230 Breast,Adj,Chemo +/- Goserelin	SWOG	01-OCT-03	83	231	458	3.0	Dec-2016	
		S0221 Breast,Adj,N+,ACvAC+G/Pac qlv2	SWOG	01-NOV-03	82	2681	3250	19.8	Jan-2013	
		B39 Stg 0-2, whole vs partial RT	NSABP	22-MAR-05			14		.0	
		C70301 QOLEmployInformCareCost Analysis	CALGB	24-OCT-05			35		.0	
		N0434 JMA27 Companion Study	NCCTG	08-DEC-05			100		.0	
		JMA27B 5yr Adj Anast vs Exemestrane	NCIC	24-APR-06			94		.0	
		PACCT-1 Assess of Ca Clinical Tests	ECOG	24-APR-06			1700		36.5	
		C40302 Endocrine +/- Inhibition	CALGB	22-SEP-06			28		1.0	
		S0500 Brst,Adv,CTC,mntain v chnge tx	SWOG	01-OCT-06	47	437	500	14.7	Jan-2011	
		E1105 Adv, Trastuzumab +/- Bev	ECOG	21-NOV-07			15		.0	
		N063D ALTTO	NCCTG	15-FEB-08			80		5.7	
		C40503 EndocrineTxCombo w/AntiVEGF Tx	CALGB	22-MAY-08			7		1.2	
N0733 Her2+, Cap + Lap +/- IMC-A12	NCCTG	30-JUL-08			2		.3			
C40601 NeoAdj, Her-2+, Pac+Trast or Lap	CALGB	08-DEC-08			5		.8			
MA.32 Metformn vs Placebo	NCIC	08-JUL-10			0					
CC	III	S0715 ALC Taxane-induced neuropathy	SWOG	15-SEP-09	11	245	380	29.5	Jan-2011	
GI	II	S0809 EHCC,Adj,Cape+Gem==>Cape+RT	SWOG	01-DEC-08	21	32	88	3.7	Dec-2011	
		S0713 Rect,Stg2-3,Ox/Cape/Cet+RT->SRG	SWOG	01-FEB-09	19	13	88	1.3	May-2015	
		S0941 GallChol,Adv,Sorafenib/Erlotinib	SWOG	15-APR-10	4	3	55	.6	May-2017	
	III	R04 Rectum, Capecitabine vs 5FU	NSABP	09-AUG-04			49		.7	
		E5202 Colon,Stg2,5FU/Leuc/Oxal +/- Bev	ECOG	08-AUG-05			356		6.7	
		C80405 GI,Met,FOLFOX/FIRI,Bev,Cetux	CALGB	26-SEP-05			527	2289	5.7	
		S0600 COLREC,MET,CHEMO+CETUX OR BEV	SWOG	15-JUN-07	38	69	671	2.0	> 15 Yrs	
		S0518 Carcinoid,Adv,Octreo/Alpha/Bev	SWOG	01-DEC-07	33	247	283	7.5	Jan-2011	
		E1208 Chemo Soraf. in Unresect HCC	ECOG	09-NOV-09			0		.0	
R0848 Panc, Adj, Erlotinib v ChemoRT	RTOG	08-DEC-09			0		.0			
C80702 Adj FOLFOX+Celecoxib or Placebo	CALGB	22-JUN-10			0					

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Temporary Closure or Closure
GU	III	MDA3410 Consolidation chemo	MDACC	08-MAY-02		21		.2	
		C90202 Pros,Bone mets,Zoledronic acid	CALGB	15-JAN-04		59		1.3	
		R0521 AS+RT vs AS+RT+Chemo	RTOG	22-DEC-05		18		.0	
		R0415 Hypofrac v Conv 3D-CRG/IMRT	RTOG	24-APR-06		1		.0	
		E2805 Renal, Adj Sunitib v Sorafinib	ECOG	08-MAY-06		583		12.0	
		E3805 CHAARTED	ECOG	08-AUG-06		62		2.7	
		R0524 Pac + Trastuzumab vs Pac alone	RTOG	08-DEC-06		5		.0	
		C90203 Pros, Surgery +/- Neoadj Chemo	CALGB	22-DEC-06		58		2.3	
		S0337 Blad, Instill Gem vs Saline	SWOG	15-JUL-07	37	138	340	8.0	Oct-2012
		PR11 Pros, Local, Watch vs Active Tx	NCIC	15-JUL-07		6		.0	
		E2804 BeST Trial	ECOG	21-MAR-08		38		1.0	
C90601 Trans cell, blind bev vs placebo	CALGB	07-AUG-09		14		2.2			
GYN	II	S0904 GYN,OVAR,Doc +/- Vandetanib,II	SWOG	15-MAR-10	5	23	132	4.1	Nov-2012
LEUK	BIOL	S9007 Cytogen. Studies in Leuk. Pts.	SWOG	15-JUL-91	229	3314		2.8	
		S9910 Leuk Central Lab/Tissue Repos	SWOG	15-APR-99	136	1265		2.7	
	II	E1905 MDS/CMMoL/AML-TLD,Aza+/-MS-275	ECOG	01-OCT-06	47	22	123	.2	
		S0535 APL,High Risk, ATRA/arsenic/GO	SWOG	15-NOV-07		34	77		Jun-2010 Temp Close
		C10403 ALL <30 yrs-Ped,Chemo. Regimen	CALGB	15-JAN-08	31	27	300	2.0	
		S0703 AML, age 60+, Azacitidine G.O.	SWOG	01-DEC-08		90	153		Jun-2010 Temp Close
		C10404 CLL, Flu/Rituxan combinations	CALGB	15-MAR-09	17	6	300	.3	
		S0919 Rel AML: Pravastatin+Ida+Ara-C	SWOG	15-AUG-09	12	7	55	.8	Jun-2015
		S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT	SWOG	01-SEP-09	12	1	94	.2	> 15 Yrs
		S0910 Rel ph-,B-ALL,Epratuzumab+Cy+Clo	SWOG	15-AUG-10	0	0	35		
III	C10603 PKC 412, blinded, FLT3 AML	CALGB	22-APR-08		13		1.3		
	E2905 MDS, Len vs Len + Epo	ECOG	09-FEB-09		12		.7		
LUNG	I-II	S0905 Mesothem,cediranib+chemo,PhI/II	SWOG	15-MAR-10	5	5	128	.9	Mar-2022
	II	S0635 Bac, Stg IIIB/IV Bev + OSI-774	SWOG	15-JUL-07	37	68	88	1.8	Jul-2011
		S0720 NSCLC,Stg I,ERCC1/RRM1 to Adj Tx	SWOG	15-NOV-08	21	39	60	3.3	Mar-2011
		S0722 Mesothelioma, RAD001	SWOG	01-DEC-08	21	29	60	1.5	May-2012

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Date of	
								Accrual Rate	Expected Closure or Temporary Closure
LUNG	II	S0709 NSCLC, Adv, PRO+, OSI-774+-Chemo	SWOG	01-DEC-08	21	8	110	.3	> 15 Yrs
		S0802 ESCLC, Topotecan+/-AVE0005, PhII	SWOG	15-MAY-09	15	78	190	7.8	Nov-2011
	III	E1505 Stg IB-III A chemo +/- Bev	ECOG	22-JUN-07		140		5.0	
		C140503 NSCL, Lobect v Sublobar resect	CALGB	09-JUL-07		9		.5	
		C30610 SCLC, Thoracic RT	CALGB	21-MAR-08		19		.7	
		S0819 NSCLC, Adv, Chemo/Bev +/-Cet	SWOG	15-JUL-09	13	200	1700	19.5	Jan-2017
	OTHER	S0424 Molecular Epidemiology NSCLC	SWOG	01-OCT-05	59	946	980	3.3	Jul-2011
LYMPH	BIOL	S8819 Lymphoma Immunophenotyping	SWOG	15-FEB-89	258	456		.7	
		S8947 Lymphoma Serum Repository	SWOG	15-APR-90	244	922		3.8	
		S9245 Relapsed Lymph Tissue Submis	SWOG	15-MAR-93	209	32		.0	
	II	S0350 NHL, PEGS, Phase II	SWOG	15-SEP-05	59	33	30	1.2	Jul-2010
		S0801 NHL, Adv, CHOP-R + I-131 + RM	SWOG	01-APR-09	17	71	80	6.0	Oct-2010
		S0816 HD, Adv, PET-Adapted Therapy	SWOG	01-JUL-09	14	62	200	6.7	May-2012
		C50604 Resp-Adapt Chemo Pos Emiss Tomo	CALGB	22-JUL-10		0			
	III	C50303 R-CHOP v EPOCH-R	CALGB	15-SEP-06		26		1.0	
		CTN0701 Relapsed follic, allo transplant	BMT-CT	23-FEB-09		0		.0	
			N						
MELAN	II	S0826 Melan, Adv, SCH 727965, Ph II	SWOG	01-JUL-09	14	55	66	1.2	Jun-2011
	III	E1697 Melan, HDIFN vs Observation	ECOG	15-OCT-02		140	1406	2.5	
MMYEL	BIOL	S0120 Asympt Monoclonal Gammopathies	SWOG	01-JUN-02	99	330	385	7.8	Apr-2011
		S0309 MMYEL Specimen Repository	SWOG	15-NOV-03	81	189		.5	
	II	S0115 Mel+PBSCT for High Risk MM+ALA	SWOG	01-JAN-04	80	103	110	.3	May-2012
	III	S0777 MM, Len Dex +/- Bortezomib	SWOG	01-APR-08	29	218	484	11.5	Aug-2012
		CTN0702 Single v Tandem Autol transplant	BMT-CT	09-JUN-10		0			
		N							

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Date of	
								Accrual Rate	Expected Closure or Temporary Closure
TM	I	S0711 Liver dysfunction PK, Dasatinib	SWOG	15-OCT-08	22	42	48	3.5	Oct-2010

Accrual goals assume studies are not terminated early as a result of interim analysis.
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
 Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

Phase	Comm.	Int Stat		Study	NCIPROTO	Ca		
		grp	Center			Cntrl	Temp	
						Study	Close	
BIOL	LEUK	Y	SWOG	S9007	Cytogen. Studies in Leuk. Pts.	SWOG-9007	N	
		Y	SWOG	S9910	Leuk Central Lab/Tissue Repos	S9910	N	
	LYMPH	N		S8819	Lymphoma Immunophenotyping		Y	
		N		S8947	Lymphoma Serum Repository		N	
		N		S9245	Relapsed Lymph Tissue Submis		N	
	MMYEL	N		S0120	Asympt Monoclonal Gammopathies		N	
		N		S0309	MMYEL Specimen Repository		N	
	CC	CC	N		S00002	SELECT Centralized Follow-up		Y
			Y	SWOG	S0702	Zoledronic Acid ONJ Registry	S0702	Y
	OTHER	CC	N		S0000B	SELECT Eye Endpoints (SEE)		Y
N				S0000D	Adenoma Colorectal Polyps (ACP)		Y	
LUNG		Y	SWOG	S0424	Molecular Epidemiology NSCLC	S0424	Y	
I	TM	N		S0711	Liver dysfunction PK, Dasatinib		N	
I-II	LUNG	N		S0905	Mesothem, cediranib+chemo, PhI/II		N	
II	BREAST	N		S0622	Breast, Adv, 2 sched Dasatinib		Y	
		N		S0800	Brst, Neoadj nabPAC+/-Bev->AC+G		N	
		Y	ACOSOG	Z1071	Node+, chemo + LN dissect	Z1071		
		Y	CALGB	C40603	Carb/Bev+Neoadj Pac, then AC/EC	CALGB-40603		
	GI	N		S0713	Rect, Stg2-3, Ox/Cape/Cet+RT->SRG		N	
		N		S0941	GallChol, Adv, Sorafenib/Erlotinib		N	
		Y	SWOG	S0809	EHCC, Adj, Cape+Gem=>Cape+RT	S0809	N	
	GYN	N		S0904	GYN, OVAR, Doc +/- Vandetanib, II		N	
	LEUK	N		S0703	AML, age 60+, Azacitidine G.O.		N	Y
				S0910	Rel ph-, B-ALL, Epratuzumab+Cy+Clo		N	
			S0919	Rel AML: Pravastatin+Ida+Ara-C		N		
Y		SWOG	S0535	APL, High Risk, ATRA/arsenic/GO	S0535	N	Y	
Y		SWOG	S0805	Ph+ ALL, Dasatinib/CVAD +/- BMT	S0805	N		

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

Phase	Comm.	Int Stat grp Center	Study	NCIPROTO	Ca Cntrl Temp Study Close
II	LEUK	Y CALGB	C10403 ALL <30 yrs-Ped,Chemo. Regimen	CALGB-10403	N
		Y CALGB	C10404 CLL, Flu/Rituxan combinations	CALGB-10404	N
		Y ECOG	E1905 MDS/CMMoL/AML-TLD,Aza+/-MS-275	E1905	N
	LUNG	N	S0635 Bac, Stg IIIB/IV Bev + OSI-774		N
		N	S0709 NSCLC, Adv, PRO+, OSI-774+-Chemo		N
		N	S0720 NSCLC,Stg I,ERCC1/RRM1 to Adj Tx		N
		N	S0722 Mesothelioma, RAD001		N
		N	S0802 ESCLC,Topotecan+/-AVE0005,PhII		N
	Lymph	N	S0350 NHL, PEGS, Phase II		N
		N	S0801 NHL, Adv, CHOP-R + I-131 + RM		N
		Y SWOG	S0816 HD, Adv, PET-Adapted Therapy	S0816	N
		Y CALGB	C50604 Resp-Adapt Chemo Pos Emiss Tomo	CALGB-50604	
	MELAN	N	S0826 Melan, Adv, SCH 727965, Ph II		N
	MMYEL	N	S0115 Mel+PBSCT for High Risk MM+ALA		N
III	BREAST	Y SWOG	S0221 Breast,Adj,N+,ACvAC+G/Pac qlv2	S0221	N
		Y SWOG	S0230 Breast,Adj,Chemo +/- Goserelin	S0230	Y
		Y SWOG	S0500 Brst,Adv,CTC,mntain v chnge tx	S0500	N
		Y CALGB	C40101 Breast, Adj, Node neg, AC vs T	C40101	
		Y CALGB	C40302 Endocrine +/- Inhibition	CALGB-40302	
		Y CALGB	C40503 EndocrineTxCombo w/AntiVEGF Tx	CALGB-40503	
		Y CALGB	C40601 NeoAdj, Her-2+, Pac+Trast or Lap	CALGB-40601	
		Y CALGB	C70301 QOLEmployInformCareCost Analysis	CALGB-70301	
		Y ECOG	E1105 Adv, Trastuzumab +/- Bev	E1105	
		Y ECOG	PACCT-1 Assess of Ca Clinical Tests	PACCT-1	
		Y IBCSG	IBC24-02 Ovar Ftn suppress/premeno	IBCSG-24-02	
		Y NCCTG	N0434 JMA27 Companion Study	N0434MA27D	
		Y NCCTG	N063D ALTTO	N063D	
		Y NCCTG	N0733 Her2+, Cap + Lap +/- IMC-A12	N0733	
		Y NCIC	JMA20 Breast, Early, Regional RT	NCICMA20	
		Y NCIC	JMA27B 5yr Adj Anast vs Exemestrane	NCIC-MA.27B	
		Y NCIC	MA.32 Metformn vs Placebo	NCIC-MA.32	
		Y NSABP	B39 Stg 0-2, whole vs partial RT	NSABP-B-39	

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

Phase	Comm.	Int Stat grp Center	Study	NCIPROTO	Ca Cntrl Temp Study Close
III	CC	N	S0701A Trmt de H.py en Latino Am		Y
		N	S0715 ALC Taxane-induced neuropathy		Y
	GI	Y SWOG	S0518 Carcinoid,Adv,Octreo/Alpha/Bev	S0518	N
		Y SWOG	S0600 COLREC,MET,CHEMO+CETUX OR BEV	S0600	N
	Y CALGB	C80405 GI, Met, FOLFOX/FIRI, Bev, Cetux	C80405		
	Y CALGB	C80702 Adj FOLFOX+Celecoxib or Placebo	CALGB-80702		
	Y ECOG	E1208 Chemo Soraf. in Unresect HCC	E1208		
	Y ECOG	E5202 Colon, Stg2, 5FU/Leuc/Oxal +/- Bev	E5202		
	Y NSABP	R04 Rectum, Capecitabine vs 5FU	NSABP-R-04		
	Y RTOG	R0848 Panc, Adj, Erlotinib v ChemoRT	RTOG-0848		
GU	N		S0337 Blad, Instill Gem vs Saline		N
		Y CALGB	C90202 Pros, Bone mets, Zoledronic acid	CALGB-90202	
		Y CALGB	C90203 Pros, Surgery +/- Neoadj Chemo	CALGB-90203	
		Y CALGB	C90601 Trans cell, blind bev vs placebo	CALGB-90601	
		Y ECOG	E2804 BeST Trial	E2804	
		Y ECOG	E2805 Renal, Adj Sunitib v Sorafinib	E2805	
		Y ECOG	E3805 CHAARTED	E3805	
		Y MDACC	MDA3410 Consolidation chemo	MDA3410	
		Y NCIC	PR11 Pros, Local, Watch vs Active Tx	NCIC-PR.11	N
		Y RTOG	R0415 Hypofrac v Conv 3D-CRG/IMRT	RTOG-0415	
Y RTOG	R0521 AS+RT vs AS+RT+Chemo	RTOG-0521			
Y RTOG	R0524 Pac + Trastuzumab vs Pac alone	RTOG-0524			
LEUK	Y	CALGB	C10603 PKC 412, blinded, FLT3 AML	CALGB-10603	
		ECOG	E2905 MDS, Len vs Len + Epo	E2905	
LUNG	Y	SWOG	S0819 NSCLC, Adv, Chemo/Bev +/-Cet	S0819	N
		CALGB	C140503 NSCL, Lobect v Sublobar resect	CALGB-140503	
		CALGB	C30610 SCLC, Thoracic RT	CALGB-30610	
		ECOG	E1505 Stg IB-IIIA chemo +/- Bev	E1505	
LYMPH	Y	BMT-CT	CTN0701 Relapsed follic, allo transplant	BMT-CTN 0701	
		N			
	Y	CALGB	C50303 R-CHOP v EPOCH-R	CALGB-50303	
MELAN	Y	ECOG	E1697 Melan, HDIFN vs Observation	E1697	N

Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center

[comchr2.sql]

Phase	Comm.	Int Stat grp Center	Study	NCIPROTO	Ca Cntrl Temp Study Close
III	MMYEL	Y SWOG	S0777 MM, Len Dex +/- Bortezomib	S0777	N
		Y	BMT-CT CTN0702 Single v Tandem Autol transplant	BMT-CTN 0702	
		N			

Southwest Oncology Group
Phase III SWOG Coordinated Open Studies
sorted by Study Id

[comchr3.sql]

Protocol Number	Study	Accrual Goal	Open Stat/Date	Months Open	Accrual as of 01Jan02	Current Accrual	Proj. Annual Accr. Rate	Expected Closure	Proj. Study Duration (Years)
S0221 S0221	Breast,Adj,N+,ACvAC+G/Pac qlv2 (BREAST)	3250	Y-11/01/03	82	2681	2681	238	Jan-2013	9.2
S0230 S0230	Breast,Adj,Chemo +/- Goserelin (BREAST)	458	Y-10/01/03	83	231	231	36	Dec-2016	13.2
S0337	Blad, Instill Gem vs Saline (GU)	340	Y-07/15/07	37	138	138	96	Oct-2012	5.2
S0500 S0500	Brst,Adv,CTC,mntain v chnge tx (BREAST)	500	Y-10/01/06	47	437	437	176	Jan-2011	4.3
S0518 S0518	Carcinoid,Adv,Octreo/Alpha/Bev (GI)	283	Y-12/01/07	33	247	247	90	Jan-2011	3.1
S0600 S0600	COLREC,MET,CHEMO+CETUX OR BEV (GI)	671	Y-06/15/07	38	69	69	24	> 15 Yrs	> 15 Yrs
S0701A	Trmt de H.py en Latino Am (CC)	1470	Y-02/01/10	7	0	0	0	> 15 Yrs	> 15 Yrs
S0715	ALC Taxane-induced neuropathy (CC)	380	Y-09/15/09	11	245	245	354	Jan-2011	1.3
S0777 S0777	MM, Len Dex +/- Bortezomib (MMYEL)	484	Y-04/01/08	29	218	218	138	Aug-2012	4.3
S0819 S0819	NSCLC, Adv, Chemo/Bev +/-Cet (LUNG)	1700	Y-07/15/09	13	200	200	234	Jan-2017	7.5

Accrual goals assume studies are not terminated early as a result of interim analysis.
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
 Accrual rate is projected from accrual in the previous six months for studies open at least three months.
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.